Published in Medical Patent Law Weekly, March 14th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at BioCryst Pharmaceuticals.
Report 1: BioCryst Pharmaceuticals, Inc., (BCRX) announced that it has initiated a pivotal trial of its lead oncology drug, Fodosine, in the treatment of patients with relapsed or refractory T-cell leukemia/lymphoma.
Initiation of this trial triggers a $5 million event payment from Mundipharma International Holdings Limited (Mundipharma) to BioCryst under the terms of the collaboration established in February, 2006 between the two...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.